ASPRE trial: risk factors for development of preterm pre‐eclampsia despite aspirin prophylaxis
Authors: Shen L. , Martinez‐Portilla R. J. , Rolnik D. L. , Poon L. C. 
Published: May 2021

ABSTRACTObjectiveTo examine the possible risk factors amongst maternal characteristics, medical and obstetric history, pre‐eclampsia (PE)‐specific biomarkers and estimated‐risk group, according to The Fetal Medicine Foundation (FMF) algorithm, that are associated with the development of preterm PE with delivery at < 37 weeks' gestation despite aspirin prophylaxis.MethodsThis was a secondary analysis of data from the ASPRE trial. The study population consisted of women with singleton pregnancy who were deemed to be at high risk for preterm PE, based on the FMF algorithm that combines maternal factors, mean arterial pressure, uterine artery pulsatility index, serum pregnancy‐associated plasma protein‐A and placental growth factor (PlGF) at 11–13 weeks' gestation. High‐risk women were randomized to receive aspirin (150 mg/day) vs placebo from 11–14 until 36 weeks' gestation. The primary outcome was PE with delivery at < 37 weeks' gestation (preterm PE). Multivariate logistic regression analysis was performed to identify independent predictors of preterm PE after adjusting for the use of aspirin and other covariates.ResultsAmong 1592 high‐risk women, the incidence of preterm PE was 3.0% (n = 48). The interaction between aspirin usage and history of chronic hypertension was significant in the prediction of preterm PE (P = 0.042), which indicated that there was no treatment effect in high‐risk women who had chronic hypertension compared with those who did not. Adjusting for aspirin use, the interaction between aspirin and chronic hypertension and other covariates, independent predictors for the development of preterm PE were PlGF multiples of the median (MoM) (adjusted odds ratio (aOR), 0.226 (95% CI, 0.070–0.723)) and estimated‐risk group based on the FMF algorithm. Compared to women with an estimated risk of 1 in 51 to 1 in 100, those with an estimated risk of 1 in 2 to 1 in 10 had a 7‐fold higher risk of developing preterm PE (aOR, 6.706 (95% CI, 2.381–18.883)), and those with an estimated risk of 1 in 11 to 1 in 50 had a 3‐fold higher risk of preterm PE (aOR, 2.769 (95% CI, 1.105–6.939)). PlGF MoM was an independent predictor for preterm PE among women with an estimated risk of 1 in 2 to 1 in 10 (aOR, 0.055 (95% CI, 0.005–0.668)). Among women with an estimated risk of 1 in 11 to 1 in 100, the use of aspirin was an independent predictor of preterm PE (aOR, 0.276 (95% CI, 0.111–0.689)). The cut‐off for PlGF with the best performance for the prediction of preterm PE was 0.712 MoM, with an aOR of 3.677 (95% CI, 1.526–8.862).ConclusionIn pregnancies at high risk of preterm PE identified by screening at 11–13 weeks' gestation using the FMF algorithm, a very high‐risk result (estimated risk ≥ 1 in 50), compared to an estimated risk of 1 in 51 to 1 in 100, chronic hypertension, compared to no chronic hypertension, and low PlGF concentration (< 0.712 MoM), compared to PlGF ≥ 0.712 MoM, were associated with the development of preterm PE despite aspirin prophylaxis. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.